¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer. - Wikidata - awgldk - TriplyDB

¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.

¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.

http://www.wikidata.org/entity/Q37582345

about

Molecular Imaging of Biomarkers in Breast Cancer Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer 18F-fluorodeoxyglucose uptake predicts PKM2 expression in lung adenocarcinoma The accuracy of (18)F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review.Quantitative Evaluation of Therapeutic Response by FDG-PET-CT in Metastatic Breast Cancer Longitudinal optical monitoring of blood flow in breast tumors during neoadjuvant chemotherapy.Imaging to study solid tumour origin and progression: lessons from research and clinical oncology.Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers.Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up.Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.Semiquantitative Parameters in PSMA-Targeted PET Imaging with 18F-DCFPyL: Variability in Normal-Organ Uptake.Clinical Significance of Pretreatment FDG PET/CT in MIBG-Avid Pediatric Neuroblastoma.Imaging Considerations and Interprofessional Opportunities in the Care of Breast Cancer Patients in the Neoadjuvant Setting.Potential Clinical Applications of 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Mammography in Breast Cancer.Prediction of Advanced Axillary Lymph Node Metastases (ypN2-3) Using Breast MR imaging and PET/CT after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma Patients.Integrated 18F-FDG PET/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy.Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters.Non-invasive Early Response Monitoring of Nanoparticle-assisted Photothermal Cancer Therapy Using F-FDG, F-FLT, and F-FET PET/CT Imaging

P2860

Q26772870-59D65CAC-CFFC-4C46-A1A3-BB57D4B30788 Q33730822-73B4495E-3425-4A34-B5F0-A7DF67D4669C Q33889303-B6C319ED-B264-45D6-8469-6FD5F40C2B72 Q36364739-4358E1DD-B9F3-4606-9706-AA3448383E59 Q36883389-FD559B43-5DBE-4269-90E6-95878ADA22EF Q38731390-A77F90F0-53F3-47B8-BD74-7615DD4FC2D4 Q39178993-B37FD71E-6E66-44D6-AAB4-D4ACD88098EB Q41491212-1BCF25DE-3D44-401E-941B-762707905D77 Q42005818-5D929E38-252D-4EF0-B723-A2BA1DD08809 Q43082312-D8F2C128-CB1A-49F1-A959-D6AACF3ADBEF Q45105171-363E9782-AC7E-4283-9E37-3A91093DFDCD Q47360425-198F1E29-1A00-4326-A908-08C6C19FC46D Q47959144-6D6123F2-FD25-42E8-8C89-15497145DCC3 Q47961966-BE09A44A-E11E-4760-8B3A-58319B8013B5 Q49912739-8D19EAA4-B140-4608-B858-6911AD0A58E7 Q50172829-E6D16259-EDAA-4A86-B148-334EBED2BDA0 Q55333524-E17F61C5-15A4-4436-8F68-D7D2DFA72E39 Q57679748-1750A88D-190D-4B09-BF49-E5FD436138DB

P2860

¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.

http://www.wikidata.org/entity/Q37582345

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.

@en

¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.

@nl

type

label

¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.

@en

¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.

@nl

prefLabel

¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.

@en

¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.

@nl

P1433

Q37582345-302D26AC-1BEF-4864-B682-2F38A0863E47

P1476

Q37582345-A9086000-57F8-4FC3-B8E6-8FF13C689D54

P2093

Q37582345-143221E4-A5EC-4DBE-A157-934E0625DA34

Q37582345-99961E8B-E09D-44A3-9C4F-8E0BB8843E2E

Q37582345-9F031920-BF6D-42ED-BCE0-D0C518D03CD9

Q37582345-A34F8632-51B4-40B4-8D74-EDCF2978931F

Q37582345-C1D6AA2C-1FBF-4747-B889-FAF0FC9F3155

Q37582345-E034F921-B8F3-4090-B7B7-1BD784BF7B29

P2860

Q37582345-056DD8E5-9D2C-47CC-8A85-2E7E37E93146

Q37582345-0692E1C6-AE04-4352-8027-1FC0F751B629

Q37582345-0B08771B-AA3A-46DE-A6BF-D0996A2A2226

Q37582345-0F6965B4-144C-4C15-9AA4-F6150D5E0A81

Q37582345-15819131-0E4C-45A9-A9B9-807E9546EFAD

Q37582345-162D76ED-BBD4-4D09-A4A3-EF4FE3B17BD6

Q37582345-1F217BAF-3016-4BA5-A370-C4D8D54D9ED6

Q37582345-22AA7C9F-5841-486E-A8FB-0E4769B29CDE

Q37582345-23C59405-02B2-470A-AE1A-2AE448F52DD5

Q37582345-29AF64C6-30C8-406A-A30D-19444836D827

P304

Q37582345-7809B4A2-C43F-4826-9105-2C8DC6B94424

P31

Q37582345-75E3C688-271C-4EB5-9AC2-508CA6F3D87B

P356

Q37582345-F0DA07EB-E0FC-48D4-A06B-65FA23630214

P407

Q37582345-9869B568-30AA-48EE-AAF1-5E81640DE2AD

P478

Q37582345-5DF66323-415C-41A7-913B-82CC59048C2E

P577

Q37582345-B85BDB01-5103-45FB-B588-52C126340666

P698

Q37582345-62B43013-B352-43E6-A476-80D1245CA683

P932

Q37582345-BA48F3B6-ECF0-416D-8A7A-C528830575C9

P356

JNUMED.115.157875

P1433

The Journal of Nuclear Medicine

P1476

¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.

@en

P2093

Bryan J Traughber

http://www.w3.org/2001/XMLSchema#string

Donna Plecha

http://www.w3.org/2001/XMLSchema#string

Norbert Avril

http://www.w3.org/2001/XMLSchema#string

Raymond F Muzic

http://www.w3.org/2001/XMLSchema#string

Shaveta Vinayak

http://www.w3.org/2001/XMLSchema#string

Stefanie Avril

http://www.w3.org/2001/XMLSchema#string

P2860

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Molecular portraits of human breast tumours

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomogr

Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer

PET/MRI hybrid imaging: devices and initial results.

P304

34S-9S

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2967/JNUMED.115.157875

http://www.w3.org/2001/XMLSchema#string

P407

P478

57 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26834099

http://www.w3.org/2001/XMLSchema#string

P932

5228521

http://www.w3.org/2001/XMLSchema#string